Avdoralimab
- Generic Name
- Avdoralimab
- Drug Type
- Biotech
- CAS Number
- 2226393-85-5
- Unique Ingredient Identifier
- DW4CE8MKS9
- Background
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Bullous Pemphigoid Pipeline Heats Up as Multiple Therapies Advance in Clinical Trials
• Bullous pemphigoid (BP), a subepidermal autoimmune blistering disease primarily affecting the elderly, currently lacks approved therapies in the United States, creating a significant unmet need.
• The BP treatment landscape is dominated by off-label corticosteroids and immunosuppressants, highlighting the urgent need for targeted and approved therapies to improve patient outcomes.
• Several therapies are in advanced Phase III clinical development, including AstraZeneca's Fasenra, Sanofi/Regeneron's Dupixent, and Akari Therapeutics' nomacopan, signaling potential paradigm shift.
• The influx of pipeline therapies aims to address unmet needs, such as diagnostic biomarkers and vulnerable patient population, and could reshape the market dynamics in bullous pemphigoid.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath